Answer
Inhaled formulations deliver high concentrations to the airways with relatively low systemic exposure and are mainly licensed for chronic Pseudomonas infection in cystic fibrosis. Injection treats serious systemic infections and requires closer toxicity monitoring.
Sources for this answer
- Bramitob Nebuliser Solution — Current selected SmPCemc · Summary of Product Characteristics
- TOBI Podhaler 28 mg inhalation powder, hard capsules — Current selected SmPCemc · Summary of Product Characteristics